Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

SWISS-APERO at 3 Years: Hints of Differences Between Amulet, Watchman Emerge

News Conference News EHRA 2025

SWISS-APERO at 3 Years: Hints of Differences Between Amulet, Watchman Emerge

April 09, 2025

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

November 18, 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

News Conference News TCT 2024

LAAO Outcomes Similar Regardless of Operator’s Specialty

October 27, 2024

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

News Conference News TCT 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

October 24, 2023

Atrial Fibrosis Mediated by Gum Disease May Be Missing AF Link

News Conference News AHA 2022

Atrial Fibrosis Mediated by Gum Disease May Be Missing AF Link

November 01, 2022

No Benefit of LAA Ligation During HeartMate 3 Implantation: MOMENTUM 3

News Conference News HFSA 2022

No Benefit of LAA Ligation During HeartMate 3 Implantation: MOMENTUM 3

Yael L. Maxwell

October 07, 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

News Conference News TCT 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

September 18, 2022

Registry Shows Watchman FLX Beating First-Gen Device for Early LAAO Outcomes

News Conference News HRS 2022

Registry Shows Watchman FLX Beating First-Gen Device for Early LAAO Outcomes

May 02, 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

News Conference News ACC 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

April 04, 2022

Amulet LAA Closure Device Has Fewer Leaks Than Watchman: Does It Matter?

News Conference News TCT 2021

Amulet LAA Closure Device Has Fewer Leaks Than Watchman: Does It Matter?

November 06, 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

News Conference News TCT 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

November 05, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

News Conference News ESC 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

August 30, 2021

New-Generation Watchman FLX Maintains Good Results Through 2 Years

News Conference News TVT 2021

New-Generation Watchman FLX Maintains Good Results Through 2 Years

July 28, 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

News Conference News ACC 2021

Low 1-Year Stroke Risk After Commercial Watchman Use

May 15, 2021

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

News Conference News ACC 2021

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

May 15, 2021

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

May 16, 2019

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

News Conference News TCT 2017

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

November 02, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.